Every year, about 795,000 people in the US have a stroke, and nearly one in four of those are recurrent. Blood clots are a major cause, and for people at high risk, like those with irregular heart rhythms or a history of clotting disorders, blood thinners are often prescribed as a preventive measure. Among these, apixaban and warfarin are two of the most commonly used medications.
This article breaks down how each drug works, their pros and cons, and when one might be preferred over the other.
Efficacy and Safety Profile
Both apixaban and warfarin are effective in preventing stroke and blood clots in patients at risk. However, studies have shown some differences in their efficacy and safety profiles.
1. For Nonvalvular Atrial Fibrillation (NVAF)
AF is a type of irregular heartbeat. When the heart beats unevenly or too fast, blood can pool in the heart, increasing the risk of blood clots, leading to a stroke. Nonvalvular AF means AF not caused by a problem with a heart valve. Apixaban is usually preferred for these patients.
A meta-analysis looked at 9 different studies involving 267,998 patients with NVAF. Results showed that people taking apixaban had a 23% lower risk of stroke or other serious blood clots than those taking warfarin. Apixaban users also had a 37% lower risk of major bleeding.
Another study used real-world data from a US medical record database from 2012 to 2016. Researchers studied 332,100 adults with NVAF and found that apixaban lowered the risk of stroke or blood clot by 16% and had a 35% lower risk of major bleeding than warfarin.
2. For Valvular Atrial Fibrillation (VAF)
Valvular AF means AF caused by a valve problem, specifically:
-
- A mechanical heart valve (artificial valve), or
- Moderate or severe mitral stenosis.
For patients with VAF, warfarin is typically recommended instead of newer anticoagulants like apixaban.
In one analysis, researchers used data from the large ARISTOTLE trial, which originally compared apixaban and warfarin in over 18,000 patients with AF. They focused on a smaller group of 251 patients who had previously undergone heart valve surgery, either with a bioprosthetic valve or a valve repair.
Within that group, apixaban appeared to be as effective and safe as warfarin. However, because the number of patients studied was small, larger studies are needed to confirm this.
Another study published in 2021 looked at 56,336 adults in the US with valvular AF who began treatment with either a DOAC (including apixaban) or warfarin between 2010 and 2019. In that study, apixaban was associated with a 46% lower risk of stroke or blood clots, and a 48% lower risk of major bleeding compared to warfarin.
Among all DOACs studied—apixaban, rivaroxaban (Xarelto), and dabigatran (Pradaxa)—apixaban showed the most favorable results.
3. For Venous Thromboembolism (VTE)
VTE is a serious condition where blood clots form in the veins. It includes:
-
- Deep vein thrombosis (DVT) – clots usually in the legs
- Pulmonary embolism (PE) – when a clot travels to the lungs
It’s the third leading cause of death from blood vessel problems in the US, after heart attacks and strokes. Each year, it affects up to 900,000 people.
Researchers compared apixaban with warfarin in elderly patients with newly diagnosed VTE using US Medicare data. They measured:
-
- Major bleeding (MB) refers to serious or life-threatening bleeding, such as bleeding in the brain or stomach.
-
- Clinically relevant non-major (CRNM) bleeding – This means bleeding that’s not life-threatening but still serious enough to need medical attention, like nosebleeds, heavy bruising, or blood in the urine or stool.
-
- Repeat (recurrent) VTE events – This refers to blood clots coming back again after someone has already had VTE. Preventing recurrent VTE is one of the main goals of using blood thinners.
The results are the following:
-
- Apixaban users had a 24% lower risk of major bleeding than those on warfarin.
- In frail patients, apixaban users had a 15% lower risk of non-major bleeding than warfarin users.
- In non-frail patients, apixaban users had a 32% lower risk of non-major bleeding.
- Risk of recurrent VTE was similar between both groups.
- People with provoked VTE (triggered by things like surgery or trauma) on apixaban had a slightly higher risk of clots coming back.
- People with unprovoked VTE on apixaban had a slightly lower risk.
Another study used data from five large US insurance claims databases to focus on patients at increased risk of bleeding/recurrences. They found that people on apixaban had:
-
- 28% lower risk of recurrent VTE events
- 30% lower risk of major bleeding
- 17% lower risk of CRNM bleeding
Both of these large studies showed that apixaban may be a safer alternative to warfarin for patients with VTE, especially for those at higher risk of bleeding or recurrence.
4. For Valvular Heart Disease (VHD)
VHD is a condition in which one or more of the heart’s valves don’t open or close properly, making it harder for blood to flow through the heart properly. Traditionally, warfarin has been the standard blood thinner for these patients.
One study showed that apixaban works just as well and safely in people with moderate or severe valve problems, as long as they don’t have mechanical valves or severe mitral stenosis.
Another study, involving people with an On-X aortic valve (a type of mechanical heart valve), demonstrated that apixaban was not as effective as warfarin in preventing clots and strokes. The trial had to be stopped early because people in the apixaban group had more strokes and clots.
At this time, warfarin is still the only approved and reliable option for people with serious VHDs or mechanical heart valves.
Onset of Action
Apixaban works faster than warfarin. After taking a single dose of apixaban, the anticoagulant effects start in 2.5 to 3.3 hours.
Warfarin is absorbed quickly and fully into the body after you take it. But even though it gets into your system fast, it doesn’t start working right away. It usually takes 1 to 3 days before it begins to thin your blood, and the full effect may take 5 to 7 days.
Because of this difference, patients starting warfarin often need a bridging anticoagulant (like heparin or enoxaparin) until it reaches full effect, while apixaban usually does not require bridging.
Side Effects
The most common side effect of both apixaban and warfarin is bleeding. However, clinical trials have shown that apixaban carries a lower risk of major bleeding than warfarin, particularly when it comes to bleeding in the brain and gastrointestinal tract.
Common bleeding events that are not life-threatening may include:
-
- Nosebleeds (epistaxis)
- Gum bleeding (especially when brushing teeth)
- Bruising easily, even from light bumps
- Heavy or prolonged menstrual bleeding
- Bleeding from cuts that takes longer to stop
- Bleeding after shaving or dental work
A study looked at how safe apixaban is compared to warfarin in people with serious kidney disease, specifically stage 4, stage 5, or those on dialysis. These patients were left out of earlier big studies on apixaban, so doctors still have questions about whether it’s safe and effective for them.
Here’s what they found:
| Bleeding Events | Apixaban | Warfarin |
|---|---|---|
| Major bleeding | 7% | 14% |
| Minor bleeding | 6% | 26% |
| Total bleeding (all types combined) | 20% | 46% |
Based on this study, apixaban might be a safer alternative to warfarin for people with advanced kidney disease, even those on dialysis, but more research is still needed to be sure.
Mechanism of Action
Apixaban works by blocking factor Xa, an enzyme needed to convert prothrombin into thrombin. Thrombin then changes fibrinogen, a protein in the blood, into fibrin. Fibrin forms thin strands that create a mesh to hold the clot in place.
By stopping factor Xa, apixaban reduces the amount of thrombin made, which leads to fewer clots. It acts on both free and clot-bound factor Xa and doesn’t require antithrombin to work. Apixaban does not interfere with platelets, so it only affects clotting proteins, not how platelets clump together.
Warfarin, on the other hand, blocks an enzyme called VKORC1. This enzyme is needed to activate vitamin K, which your liver uses to make clotting proteins. Without active vitamin K, your body can’t produce enough of the clotting factors needed to form clots.
Dosing and Administration
For apixaban, no routine blood testing is needed. The dose is fixed and doesn’t change often. Warfarin, on the other hand, requires regular INR blood tests to check how thin the blood is. The dose is adjusted based on INR results, which can be affected by diet, other medications, and health changes.
Below is a comparison of the dosing guidelines for apixaban and warfarin:
| Indication | Apixaban | Warfarin |
|---|---|---|
| Available Strength | 2.5 mg and 5 mg tablets | 1 mg, 2mg, 2.5mg, 3mg, 4mg, 5mg, 6mg, 7.5mg, and 10mg tablets |
| Atrial Fibrillation (to prevent stroke and systemic embolism) | 5 mg twice daily is standard.
Use 2.5 mg twice daily if the patient has any 2 of these:
|
Dose varies per patient. Adjusted to keep INR between 2.0-3.0. It usually starts at 2-5 mg once daily, then is adjusted based on INR blood test results. |
| Treatment of Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE) | Start with 10 mg twice daily for 7 days, then switch to 5 mg twice daily. | Typically started with heparin or enoxaparin first (overlap therapy). Warfarin is started at the same time and adjusted to reach INR 2.0-3.0. Once INR is stable, the injectable anticoagulant is stopped. |
| DVT/PE Prevention After Initial Treatment (Extended Use) | 2.5 mg twice daily after at least 6 months of initial treatment. | Continued at the dose needed to keep INR 2.0-3.0. Duration and intensity depend on the risk of recurrence. |
| Prevention of DVT After Hip or Knee Replacement Surgery | 2.5 mg twice daily.
|
Warfarin is not routinely used for this purpose anymore due to the need for INR monitoring and a delayed onset of action. |
| Mechanical Heart Valve or Moderate-to-Severe Mitral Stenosis | Not recommended. Apixaban is not approved for patients with mechanical heart valves or severe mitral valve disease. | Warfarin is the drug of choice. INR target depends on the valve type and position (usually 2.5-3.5). |
Drug Interactions and Monitoring
Apixaban is easier to manage day-to-day, with fewer interactions and no need for regular blood tests, but still requires attention to renal function and drug metabolism pathways. Warfarin requires close monitoring and has more dietary and drug interactions, but allows for fine-tuning of dose based on INR, which can be beneficial for certain high-risk patients.
Here’s how they differ:
Drug Interactions
| Aspect | Apixaban | Warfarin |
|---|---|---|
| Enzyme interactions | Metabolized mainly by CYP3A4 and a substrate of P-glycoprotein (P-gp). | Metabolized by multiple CYP enzymes, mainly CYP2C9, CYP1A2, and CYP3A4. |
| Common interaction risk | Interacts with strong CYP3A4 and P-gp inhibitors/inducers (e.g., ketoconazole, rifampin). | Interacts with many drugs, including antibiotics (e.g., metronidazole, erythromycin), antifungals, anti-seizure meds, NSAIDs, and more. |
| Diet interactions | No interaction with vitamin K-containing foods. | Strong interaction with vitamin K-rich foods (e.g., spinach, kale), which can reduce warfarin’s effect. |
| Alcohol | May increase bleeding risk if taken excessively. | Can increase INR or liver toxicity. Regular use may affect warfarin metabolism. |
| OTC/Herbal interactions | Caution with NSAIDs and some supplements (e.g., St. John’s Wort, ginger/garlic). | Interacts with many herbs (e.g., ginseng, ginkgo, cranberry) and OTC meds (e.g., aspirin, ibuprofen). |
| Antibiotics and antifungals | Moderate risk. Monitor if co-administered with strong inhibitors/inducers. | High risk of INR fluctuations—many require dose adjustment or close INR monitoring. |
Monitoring Requirements
| Aspect | Apixaban | Warfarin |
|---|---|---|
| Routine blood testing | Not required for routine monitoring. | Regular INR testing is essential to ensure therapeutic effect. |
| Monitoring target | No lab test needed, but watch for signs of bleeding or clotting. | Maintain INR between 2.0–3.0 (or 2.5–3.5 for certain conditions). |
| Renal function | Requires baseline and periodic monitoring, especially in elderly or patients with kidney issues. | Not renally cleared; no adjustment needed based on kidney function. |
| Liver function | Caution in severe hepatic impairment; monitor if liver disease is suspected. | Also requires caution; impaired liver function can affect INR. |
| Patient self-management | No home test kits; adherence and symptom awareness are key. | INR can be self-monitored at home with approved kits for some patients. |
Reversal Agents
Reversal agents are medications that help stop the effect of anticoagulants (blood thinners). They’re used when a person is bleeding heavily or needs emergency surgery. In these situations, it’s important to quickly restore the blood’s ability to clot.
For Apixaban
Andexanet alfa (brand name Andexxa®) is a reversal drug made to counter the effects of apixaban and other factor Xa inhibitors. It’s a lab-made protein that looks like human factor Xa, which lets it attach to these blood thinners.
However, it’s slightly altered so it doesn’t act like a clotting factor itself. Instead, it simply soaks up the factor Xa inhibitors, helping the blood clot normally again. It also blocks a protein that slows down clotting, which boosts thrombin and helps stop bleeding faster.
In the ANNEXA-A and ANNEXA-R studies, Andexanet alfa reversed the blood-thinning effect of apixaban in just a few minutes and kept working during the infusion. Another study showed it lowered anti-factor Xa activity within two minutes. Common side effects include urinary tract infections, pneumonia, and reactions related to the infusion.
There are two dosing options:
-
- Low Dose: 400 mg IV bolus at 30 mg/min, then a 2-hour IV drip at 4 mg/min
- High Dose: 800 mg IV bolus at 30 mg/min, then a 2-hour IV drip at 8 mg/min
For apixaban, here’s the general dosing guideline:
| Last Apixaban Dose | < 8 Hours Prior/Unknown to the last dose of Apixaban | 8 Hours or More Prior to the last dose of Apixaban |
|---|---|---|
| 5 mg or less | Low dose | Low dose |
| > 5 mg / unknown | High dose | Low dose |
For Warfarin
The primary reversal agent for warfarin is vitamin K (Phytonadione). It reverses the anticoagulant effect of warfarin by helping the liver produce clotting factors II, VII, IX, and X. Oral vitamin K (2.5 mg or more) works in about 2 to 24 hours, with full effect by 24 to 36 hours.
IV vitamin K works faster, within 6 to 12 hours, but can rarely cause allergic reactions. Oral vitamin K is best for patients with high INR but no active bleeding.
For urgent cases like major bleeding or surgery, vitamin K alone isn’t fast enough, so other methods are needed too, including:
-
- Fresh Frozen Plasma (FFP): FFP contains natural clotting factors from donor blood and can help reverse warfarin. It works, but it takes longer to infuse and needs larger volumes. FFP is still useful, but doctors now prefer faster options like PCC during emergencies.
-
- Prothrombin Complex Concentrates (PCC): PCC is a concentrated blood product that contains key clotting factors (II, IX, X, and sometimes VII). It works quickly and in small volumes. A small PCC dose (40 mL) can have the same effect as a full unit of FFP (1000 mL).
-
- Infusion of Individual Clotting Factors: These are very purified versions of clotting factors (II, VII, IX, X) used to reverse warfarin. They work fast and are useful in emergencies. But they are hard to get, expensive, and used only in special cases due to limited supply and strict screening.
Takeaway
Apixaban and warfarin are both effective blood thinners, but they differ in several important ways. Apixaban is often preferred for nonvalvular atrial fibrillation and VTE because it lowers the risk of major bleeding and doesn’t require routine blood testing. It also starts working faster and has fewer food and drug interactions.
Warfarin, on the other hand, is still the only approved option for people with mechanical heart valves or severe mitral stenosis. It’s also much cheaper, especially in the US, where apixaban is only available as the brand name Eliquis and can cost hundreds of dollars more per month.
For most people without valve issues, apixaban may be safer and easier to manage. But for those who need close dose control or can’t afford newer medications, warfarin remains a practical choice. Always talk to your doctor before making a switch.
Frequently Asked Questions
Related Articles
Sources
Memon, R. A., Hamdani, S. S. Q., Usama, A., Aisha, F., Kundi, H., Mathavan, M., Khalid, M., & Khan, A. (2022). Comparison of the efficacy and safety of Apixaban and Warfarin in the prevention of stroke in patients with non-valvular atrial fibrillation: A Meta-Analysis. Cureus. https://doi.org/10.7759/cureus.27838
Wanat, M. A., Wang, X., Paranjpe, R., Chen, H., Johnson, M. L., Fleming, M. L., & Abughosh, S. M. (2019). Warfarin vs. apixaban in nonvalvular atrial fibrillation, and analysis by concomitant antiarrhythmic medication use: A national retrospective study. Research and Practice in Thrombosis and Haemostasis, 3(4), 674–683. https://doi.org/10.1002/rth2.12221
Guimarães, P. O., Pokorney, S. D., Lopes, R. D., Wojdyla, D. M., Gersh, B. J., Giczewska, A., Carnicelli, A., Lewis, B. S., Hanna, M., Wallentin, L., Vinereanu, D., Alexander, J. H., & Granger, C. B. (2019). Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: Insights from the ARISTOTLE trial. Clinical Cardiology, 42(5), 568–571. https://doi.org/10.1002/clc.23178
DOACs vs. Warfarin in Patients With Valvular Atrial Fibrillation – American College of Cardiology. (2021, April 6). American College of Cardiology. https://www.acc.org/Latest-in-Cardiology/Journal-Scans/2021/04/06/18/29/Effectiveness-and-Safety-of-Direct
Guo, J. D., Hlavacek, P., Rosenblatt, L., Keshishian, A., Russ, C., Mardekian, J., Ferri, M., Poretta, T., Yuce, H., & McBane, R. (2020). Safety and effectiveness of apixaban compared with warfarin among clinically-relevant subgroups of venous thromboembolism patients in the United States Medicare population. Thrombosis Research, 198, 163–170. https://doi.org/10.1016/j.thromres.2020.11.039
Cohen, A. T., Sah, J., Dhamane, A. D., Hines, D. M., Lee, T., Rosenblatt, L., Emir, B., Keshishian, A., Yuce, H., & Luo, X. (2023). Effectiveness and Safety of Apixaban vs Warfarin in Patients with Venous Thromboembolism with Risk Factors for Bleeding or for Recurrences. Advances in Therapy, 40(4), 1705–1735. https://doi.org/10.1007/s12325-023-02440-1
Avezum, A., Lopes, R. D., Schulte, P. J., Lanas, F., Gersh, B. J., Hanna, M., Pais, P., Erol, C., Diaz, R., Bahit, M. C., Bartunek, J., De Caterina, R., Goto, S., Ruzyllo, W., Zhu, J., Granger, C. B., & Alexander, J. H. (2015). Apixaban in comparison with Warfarin in patients with atrial fibrillation and valvular heart disease. Circulation, 132(8), 624–632. https://doi.org/10.1161/circulationaha.114.014807
Wang, T. Y., Svensson, L. G., Wen, J., Vekstein, A., Gerdisch, M., Rao, V. U., Moront, M., Johnston, D., Lopes, R. D., Chavez, A., Ruel, M., Blackstone, E. H., Becker, R. C., Thourani, V., Puskas, J., Al-Khalidi, H. R., Cable, D. G., Elefteriades, J. A., Pochettino, A., . . . Alexander, J. H. (2023). Apixaban or Warfarin in Patients with an On-X Mechanical Aortic Valve. NEJM Evidence, 2(7). https://doi.org/10.1056/evidoa2300067
Budovich, A., Zargarova, O., & Nogid, A. (2013, April 1). Role of Apixaban (Eliquis) in the treatment and prevention of thromboembolic disease. https://pmc.ncbi.nlm.nih.gov/articles/PMC3684191/
Herndon, K., Guidry, T. J., Wassell, K., & Elliott, W. (2019). Characterizing the safety profile of Apixaban versus Warfarin in moderate to severe chronic kidney disease at a Veterans Affairs hospital. Annals of Pharmacotherapy, 54(6), 554–560. https://doi.org/10.1177/1060028019897053
Luo, Y., Ma, C., & Yu, Y. (2022). Application of fresh frozen plasma transfusion in the management of excessive warfarin-associated anticoagulation. Blood science (Baltimore, Md.), 4(2), 57–64. https://doi.org/10.1097/BS9.0000000000000108
Siegal, D. M., Curnutte, J. T., Connolly, S. J., Lu, G., Conley, P. B., Wiens, B. L., Mathur, V. S., Castillo, J., Bronson, M. D., Leeds, J. M., Mar, F. A., Gold, A., & Crowther, M. A. (2015). Andexanet Alfa for the reversal of factor XA inhibitor activity. New England Journal of Medicine, 373(25), 2413–2424. https://doi.org/10.1056/nejmoa1510991
Momin, J. H., Candidate, P., & Hughes, G. J. (2019, September 1). Andexanet Alfa (Andexxa®) for the reversal of direct oral anticoagulants. https://pmc.ncbi.nlm.nih.gov/articles/PMC6705484/
Agrawal, A., Kerndt, C. C., & Manna, B. (2024, February 22). Apixaban. StatPearls – NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK507910/
Patel, S., Singh, R., Preuss, C. V., & Patel, N. (2024, October 5). Warfarin. StatPearls – NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK470313/
